RxDoctor Payments Data

Sudha Rani, MD

Nephrology · Lafayette, INNPI 1811916083

Payments from drug & device makers

$1,807in general payments, 2019–2025

Across 92 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$464
  • Vifor Pharma, Inc.$365
  • Mallinckrodt Hospital Products Inc.$205
  • Boehringer Ingelheim$158
  • Amgen$121
  • Novartis$107
  • plus $387 from 10 others

What the payments were for

  • Food & beverage$1,68493%
  • Education$1237%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,807 in reported general payments places this provider in the 60th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$301,091
Medicare patients
602
Services billed
2,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin94$135,723
VelphoroSucroferric Oxyhydroxide38$129,920
FarxigaDapagliflozin Propanediol126$111,088
XphozahTenapanor Hcl16$67,203
RayaldeeCalcifediol33$58,822
LokelmaSodium Zirconium Cyclosilicate18$34,548
VeltassaPatiromer Calcium Sorbitex21$29,235
Sevelamer Carbonate116$20,224
MyrbetriqMirabegron12$11,889
JanuviaSitagliptin Phosphate12$9,224
Lanthanum Carbonate14$8,794
Demeclocycline Hcl21$6,332
Combivent RespimatIpratropium/Albuterol Sulfate12$6,090
EntrestoSacubitril/Valsartan12$5,847
Febuxostat21$5,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$464$145,636144 claims
Boehringer IngelheimJardiance, Combivent Respimat$158$141,813106 claims
Fresenius USA Marketing, Inc.Velphoro$51$129,92038 claims
OPKO Pharmaceuticals, LLCRayaldee$93$58,82233 claims
NovartisEntresto$107$5,84712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 238 nephrology providers in Indiana.

Other nephrology in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →